

INDEX

Yue, Y.595(NT)	Zhang, S.189	Zhou, L-Q.1160	Zlokovic, B.V.718(L)
Z	Zhang, Z-X.782	Zhu, A.643	Zobywalski, A.332
Zamvil, S.S.1098(NV)	Zhao, G.464	Zhu, B.62	Zöller, G.32
Zanelli, E.629(NV)	Zhao, Q.H.871	Zhu, G.283	Zou, Y.189
Zeng, W.455	Zhao, X.1160	Zhu, H.643	Zuckier, L.S.871
Zhang, D.556	Zhao, X-Y.703, 939(Err)	Zhu, S.797	Zuscik, M.J.1388
Zhang, L.82, 736(NV), 782	Zheng, T.S.1241	Zimhony, O.1043	
Zhang, M.196	Zhong, R.549	Zion, D.615(C)	
	Zhou, H.460, 1160	Zisman, A.924	

2000 Subject index • Volume 6

**nature
medicine**

No. 1	1–111	No. 7	717–838
No. 2	113–229	No. 8	839–939
No. 3	231–356	No. 9	941–1062
No. 4	357–480	No. 10	1063–1191
No. 5	481–603	No. 11	1193–1293
No. 6	605–715	No. 12	1295–1429

(L)	Letter to the Editor
(N)	News
(B)	Book Review
(C)	Commentary
(NV)	News & Views
(NT)	New Technology
(Corr)	Correction
(Err)	Errata

A

Abbott Laboratories, countersuit against, 948(N)
 Academic medical centers, industry support group, 948(N)
 Achromatopsia, genetic mutation, 746(NV)
Acid sphingomyelinase gene disruption, oocyte apoptosis suppression, 1100(NV), 1109
 Activin A, and basic fibroblast growth factor neuroprotective effect, 739(NV), 812
 Acute promyelocytic leukemia, transcriptional defects, 742(NV)
 Adeno-associated virus vector
 viral DNA heterodimerization, 599(NT)
 see also Recombinant adeno-associated virus vector
 Adenovirus E1A, and Ewing tumors, 4(L)
 Adenovirus mutant *d1520* replication, p14^{ARF} mechanism, 1128
 Adenovirus mutant *d922-947*, anti-tumoral efficacy, 1134
 Adipogenesis inhibition, AP-1 transcription factor, 970(NV), 985
 Adult hippocampal progenitor cells, retinal dystrophy grafts, 1211(NV)
 Africa
 HIV vaccine trials, 844(N)
 UN acknowledges HIV/AIDS threat, 117(N)
 Aging, DNA microarray analysis, fibroblasts, 507(NV)
 AIDS, African epidemic, UN acknowledges threat, 117(N)
 AIDS vaccine, 1220(NV). See also HIV vaccine
 Akt activation, statin mechanism of action, 965(NV), 1004
 Albinism, gene therapy approach, mice, 27(NV)
 Alcohol intake, fetal neurotoxicity mechanisms, 263(NV)
 Allogeneic bone marrow transplantation. See Bone marrow transplantation

Allografts. See Transplantation
 Alpha-hemolysin, urinary tract pathogenesis, 741(NV)
 Altered-peptide ligand, multiple sclerosis clinical trials, 1098(NV), 1167, 1176
 Alternative medicine, 240(N)
 Alzheimer disease
 amyloid β -peptide antibody treatment, mice, 916
 amyloid β -peptide improper clearance, 133(NV), 143
 ibuprofen treatment
 magnetic resonance microscopy, 20(NV)
 American Heart Association, stem cell research support, 845(N)
 δ -aminolevulinic acid dehydratase import mechanism, 898
 AMPA antagonists, multiple sclerosis potential use, 15(NV), 62, 67
 Amygdala, morphine sensitization, SPARC glycoprotein, 910
 Amyloid-A-induced RAGE upregulation, 633(NV), 643
 Amyloid β -peptide
 antibody treatment, mouse model, 916
 catabolic pathway identification, 133(NV), 143, 718(L)
 microvascular endothelium transport, 718(L)
 pathological deposition mechanism, 133(NV), 143
 Amyloid β -protein precursor
 cytotoxic proteolytic peptide derivation, caspase cleavage, 385(NV), 397
 neurodegeneration direct role, 512(NV)
 Amyloid plaques, magnetic resonance microscopy, 20(NV)
 Amyloidosis
 amyloid-A-induced RAGE upregulation, 633(NV), 643

and yeast prions, 751(R)
 Anderson, Roy, 1070(N)
 Androgen escape mechanism, prostate cancer, 628(NV), 703, 933(Err)
 Anergy, p27^{HP1} function, 290
 Ang1, dermal vessels effect of, 131(NV)
 Angiogenesis
 Ang1 and VEGF effect, 131(NV)
 ischemic peripheral neuropathy therapy, VEGF gene transfer, 379(NV), 405
 maspin inhibition of, 196
 mechanisms and therapeutic application, 389(R)
 PR39 regulation of, 49, 356(Err)
 thrombospondin-1 inhibition of, signals, 41
 tumor and wound healing mechanism, 979(NV)
 vascular endothelial growth factor gene therapy risk, 1102(NV)
 xenogeneic endothelial cell anti-tumor immunotherapy, 1160
 Angioma-gensis, VEGF gene therapy risk, 1102(NV)
 Angiopoietin-1, adult vasculature leakage protection, 460
Ank mouse arthritis model, genetic defect elucidated
 Anthrax, Russian outbreak investigation, 245(B)
 Antibiotics
 deterrence of resistance to, 142(NV)
 VncS-VncR pathway target, 263(NV)
 Antigen-specific regulatory T cells, 782
 Antigen-specific T cells, *in situ* detection, 1056(NT)
 Anti-infective biomaterials, screening, 1053(NT)
 Anti-inflammatory effects, carbon monoxide, 422
 Anti-retroviral therapy. See Highly active anti-retroviral therapy
 Anti-tumor therapy. See Cancer therapy
 AP-1 transcription factors, bone formation,

- 970(NV),980,985
- Apoptosis**
 mitochondrial control, 513(R)
 thrombospondin-1 induction of, signals, 41
 TRAIL induction of, hepatocytes, 502(NV),564
- Aquaporin-4 deletion, cerebral edema reduction,**
 159
- Arginine-cyclosporin A conjugation, topical delivery,**
 1253
- Arntzen, Charles,** 364(N)
- Arteriogenesis, mechanisms,** 389(R)
- Atherosclerosis, herpesvirus role,** 979(N)
- Attention deficit/hyperactivity disorder, basal ganglia functional deficits, MRI,** 470
- Australia**
 biomedical lobbying group created, 613(N)
 Celera Genomics Corporation deal, 847(N)
 Ogilvie's research funding warning, 725(N)
 scientists' discontent, survey, 10(N)
 universities told to commercialize, 120(N)
- Australian Aborigines, group A streptococcal vaccine,** 455
- Autoimmune disease**
 CD40 agonistic antibodies, arthritis, 629(NV),673
 gram-negative infection link, molecular mimicry model, 215
 human cytomegalovirus link, 1183
 and thymocyte positive selection disruption, 259(NV),298
- Autoimmune T cells, multiple sclerosis,** 15(NV),56
- B**
 B-cell inhibition, limitin role, 659
 B-cell malignancies, T-cell response induction, 667
 B-cell mitogen identification, pathogenic trypanosome, 865(NV),890
 Barbacid, Mariano, 239(N)
 Basal ganglia functional deficits, attention deficit/hyperactivity disorder, 470
 Basic fibroblast growth factor neuroprotection, and activin A induction, 739(NV),812
 Baylor University, science and religion center controversy, 613(N)
 BBB scale scores, 358(L)
 Bcl-2 oncoprotein, chemoresistance mechanism, 1029
 Beanie Baby profits, AIDS Foundation support, 726(N)
 β -cell induction, PDX-1 role, hepatocytes, 505(NV),568
 β -human chorionic gonadotropin, in tumor assessment, 711(NT)
 Bioengineering, FY00 congressional priority, 7(N)
 Bioethics, 615(C)
 Bio-flavonoids, infant leukemias role, 512(NV)
 Bioinformatics, and functional genomics, 1071(N)
 Biomaterials, anti-microbial screening, 1053(NT)
 Biomedical education, 'Supercourse' proposal, 358(L)
 Biomedical publication, ethics, 1205(B)
 Biomedical research
- survey shows secrecy in, 365(N)
 trends, 113(E)
- Blood stem cells, renal cell carcinoma treatment,**
 1107(NV)
- Blower, Sally,** 359(N)
- Bone cancer pain, osteoprotegerin treatment,**
 504(NV),521,838(Err)
- Bone formation,**
 AP-1 transcription factor family in, 970(NV),980,985
 statin stimulation of, 21(NV)
- Bone marrow transplantation**
 and co-stimulatory blockade, macrochimerism and tolerance induction, 464
 graft-versus-host disease prevention, 18(NV)
 "facilitating cells" surface marker, 866(NV),904
- Books reviewed**
Anthrax: The Investigation of a Deadly Outbreak, 245
Cancer: The Evolutionary Legacy, 496
Darwin's Ghost: The Origin of Species Updated, 621
Defending the Cavewoman, 371
The Door in the Dream: Conversations With Eminent Women in Science, 1089
Driving Mr. Albert: A Trip Across America with Einstein's Brain, 1090
Ethical Issues in Biomedical Publication, 1205
A Fever in Salem: A New Interpretation of the New England Witch Trials, 127
Flu: The Story of the Great Influenza Pandemic of 1918 and the Search for the Virus that Caused It, 12
Genome: The Autobiography of a Species in 23 Chapters, 11
The Methuselah Gene: A Science Fiction Adventure Thriller, 857
Neural Transplantation, 621
Of Mice, Men, and Microbes-Hantavirus, 11
The Paradox of Sleep, 245
The Shape of the Heart, 857
Stress, Coping, and Depression, 733
To America's Health: A Proposal to Reform the Food and Drug Administration, 963
The Triple Helix: Gene, Organism and Environment, 1206
Virus: The Co-Discoverer of HIV Tracks Its Rampage and Charts the Future, 372
Xeno: The Promise of Transplanting Animal Organs into Humans, 963
- Borst, Piet,** 8(N)
- Bovine spongiform encephalopathy,** 258(NV)
- Brain edema, aquaporin-4 modulating role,** 159
- Brain tumors**
 magnetic resonance spectroscopy, nosologic images, 1287(NT)
 neural stem cells, gene therapy vehicle, 369(C),447
- Brazil, research centers long-term support,** 1198(N)
- BRCA test, NIH pays cut-rate prices,** 610(N)
- Breast cancer**
 iodide transporter expression, 859(NV),871
 selective estrogen receptor modulators, 960(C)
- Bullous impetigo, exfoliative toxin A mechanism,**
 1213(NV),1275
- C**
 Calcineurin, and heart failure, 2(L)
 Calcium signaling, cardiac growth/function, 1221(R)
- Canada**
 health research legislation, 8(N)
 networked research expansion, 240(N)
- Cancer**
 clinical trial insurance coverage agreement, 1212(N)
 evolutionary legacy, 496(B)
 metastasis model, 100
 transcription regulation
- Cancer research**
 UK NCI proposal, 357(E)
 UK parliamentary committee inquiry, 360(N)
 UK report suggests improvements, 945(N)
- Cancer therapy**
 adenovirus mutant *d1520* replication facilitation, 1128
 adenovirus mutant *d1922-947*, 1134
 cannabinoid agonists, 255(NV),313
 Fc receptors cytotoxicity role, 373(NV),4434
 gene therapy clinical trial, 862(NV),879
 MGATS inhibitors potential, 306
 vesicular stomatitis virus, 821
- Cancer vaccine**
 renal carcinoma, 252(NV),332
 TERT RNA transfected dendritic cells, 966(NV),1011
 xenogeneic endothelial cells, 1160
- Cannabinoids, anti-tumor action,** 255(NV),313
- Carbon monoxide, anti-inflammatory effects, mechanism,** 422
- Carcinoembryonic antigen, positron emission tomography,** 869(NV)
- Cardiac failure. See Heart failure**
- Cardiac growth/function, calcium signaling,**
 1221(R)
- Cardiac hypertrophy**
 calcium signaling, 1221(R)
 myocyte adaptation, myosin light chain kinase, 183
 TAK1 role, transgenic mice, 556
 transgenic mice models, need for controls, 482(L)
- Cardiomyocytes**
 HF- β null mice, 968(NV)
 myosin light chain kinase role, hypertrophy, 183
- Cardiovascular disease, bacterial infections role,**
 841(L)
- Carlsson, Arvid,** 1196(N)
- Carney complex gene discovery,** 979(NV)
- Caspase activation, compensatory pathways,** 1241
- Caspase-cleaved amyloid β -protein precursor, cyto-**

- toxic proteolytic peptide generation, 385(NV),397
- Caspase 8 suppression, neuroblastoma *MYCN* amplification, 498(NV),529
- CCR5 co-receptor, intercellular transfer, 769
- CD4 co-receptor function, video microscopic analysis, 1097(NV)
- CD8⁺ bone marrow transplant facilitating cell, surface marker, 866(NV), 904
- CD8⁺ cells
HIV homeostasis impact, 976(NV),1036
virus- and tumor-specificity detection, 1056(NT)
- CD34⁺ cells, flow cytometry counting, 833(NT)
- CD36, thrombospondin-1 antiangiogenic activity mediation, 41
- CD40 agonistic antibodies, in chronic autoimmune inflammatory disease, 629(NV),673
- CD40 ligand
blockade of, thromboembolic complications, 114(L)
dendritic cell expression, CD4⁺ cell-independent immunity, 1154
- CD45 mutations, severe combined immunodeficiency disease, 343
- Celera Genomics sequence data, financial optimism, scientific skepticism, 116(N)
- Celiac disease, dominant A-gliadin T-cell epitope identification, 337
- Cell death, mitochondrial control, 513(R)
- Cell physiology, 1087(C)
- Cell signaling 'glue grant,' 1072(N)
- Cellular transformation, transcriptional regulation, 742(NV)
- 'Central DNA flap,' 626(NV)
- Ceramide accumulation, cannabinoid apoptosis mechanism, 255(NV),313
- Ceramide analogs, infertility protection potential, 1100(NV),1109
- Cerebral edema, aquaporin-4 modulating role, 159
- Chagas disease
NSAIDs potential use in, 142(NV)
proline racemase as B-cell mitogen, 865(NV), 890
- Challenge Grants program, 1197(N)
- Chemokines, T-cell repulsive response, 543
- Chemoresistance analysis, murine lymphoma model, 1029
- Chemotherapy
dosage design, 500(NV)
ONYX-015 combination, clinical trial, 862(NV), 879
- Chimpanzees, US sanctuary system, 9(N)
- China, first international HIV vaccine meeting, 5(N)
- Cholesterol homeostasis, retinoid X receptor role, 1104(NV)
- Cholesteryl ester transfer protein inhibitor, 869(NV)
- Chronic fatigue syndrome, GAO funding controversy report, 846(N)
- Chronic myelogenous leukemia, T-cell immunity in elimination of, 1018
- Cis*-activation strategy, recombinant adeno-associated virus vector, 595(NT)
- Clinical research
industry support, 948(N)
NIH progress report, 1201(C)
- Clinical scientists, UK plans, 490(N)
- Clinical trials research, standards, 1193(E)
- ClinicalTrials.gov, 365(N)
- Celiac disease. *See* Celiac disease
- Collagen-induced arthritis, CD40 agonist antibody treatment, 629(NV), 673
- Colonic fluid production, galanin-1 receptor up-regulation, 1048
- Colony-stimulating factor, placental immunity role, 589
- Colorectal cancer, combinatorial chemoprevention, 874(NV), 1024
- Combinatorial chemoprevention, intestinal neoplasia, 974(NV), 1024
- Combined co-stimulatory blockade failure, transplant model, 115(L)
- Congestive heart failure. *See* Heart failure
- Cortisol-responsive androgen receptor mutants, prostate cancer, 628(NV), 703
- Coxsackievirus-mediated heart disease
tyrosine kinase p56^{lck} role, 429
viral damage versus molecular mimicry model, 631(NV), 693
- Creutzfeldt-Jakob disease, 'new variant,' 258(NV)
- Crohn disease, interleukin 6 *trans* signaling role, 583
- CTLA-4 blockade, T-cell paradoxical inhibition, heterogeneity, 211
- Cyclooxygenase signaling inhibition, combinatorial chemoprevention, 974(NV), 1024
- Cyclopentenone prostaglandins, anti-inflammatory mechanism, 137(NV)
- Cyclosporin A-arginine conjugation, topical delivery, 1253
- Cysteine protease calpain 10 gene, Type II diabetes, 1107
- Cytokines
heat-shock protein-70 production of, 429
transplantation rejection regulation, 497(NV), 549
- Cytomegalovirus infection, autoimmunity link, 1183
- Cytotoxic T cells, leukemia elimination, 1018
- D**
- Darwin's theory, 621(B)
- DDT, balance of risk paradigm, 729(C)
- Declaration of Helsinki, 615(C)
- Δ -aminolevulinic acid dehydratase import mechanism, 898
- Demyelinating diseases, endogenous sodium channel blocker role, 738(NV), 808
- Dendritic cells
CD40L expression, and CD4 cell-independent immunity, 1154
Dengue virus target, 748(NV), 816
scrapie pathogenesis role, 719(L)
TERT RNA transfection, tumor immunity, 966(NV), 1011
- tumor cell hybrid vaccine, renal carcinoma, 252(NV), 332
- Dengue virus, dendritic cells target of, 748(NV), 816
- Dentate gyrus, neuronal progenitor cell isolation, 249(NV), 271
- Depression, and stress, 733(B)
- Desmoglein 1, exfoliative toxin A target, 1213(NV), 1275
- Diabetes mellitus *See* Type I diabetes; Type II diabetes
- Diarrhea, infectious, galanin-1 receptor up-regulation, 1048
- Dickman, Michael, 121(N)
- Diltiazem, rod photoreceptor rescue, 116(L)
- Disability Adjusted Life Expectancy, 722(N)
- Disgust, specialized brain system, 1220(NV)
- dI922-947, anti-tumoral efficacy, 1134
- dI1520 adenovirus mutant, replication facilitation, 1128
- DNA microarray analysis, fibroblast aging mechanism, 507(NV)
- DNA mismatch repair. *See* Mismatch repair
- DNA vaccine
fetal oral cavity administration, 929
measles, 744(NV), 776, 1062(Err)
- Doxorubicin-peptide 'prodrug,' 1248
- Dreaming, 245(B)
- Drosophila*, nucleotide sequence revealed, 387(NV)
- Drug addiction, neurotrophic factors role, 635(NV)
- Drug resistance analysis, murine lymphoma model, 1029
- Duchenne muscular dystrophy, gene therapy, golden retrievers, 6353(NV)
- Dysentery, 'probiotic' treatment, 257(NV), 265
- E**
- Ebola virus glycoprotein, pathogenicity determinant, 886
- Einstein's brain, 1090(B)
- Embryonic stem cells. *See* Human embryonic stem cells
- Endothelial xenogeneic cells, antitumor immunotherapy, 1160
- Environmental endocrine hypothesis, 246(B)
- Epidermal growth factor inhibition, combinatorial chemoprevention, 974(NV), 1024
- Epidermal powder immunization, 1187(NT)
- Erythrocytes, ring stage *P. falciparum* infection, 1264
- Escherichia coli* infection
 α -hemolysin urinary tract pathogenesis, 741(NV)
'probiotic' treatment, 257(NV), 265
- Ethics. *See* Research ethics
- Ewing tumors, and adenovirus E1A, 4(L)
- Exfoliative toxin A, epidermal blistering mechanism, 1213(NV), 1275
- Experimental autoimmune encephalomyelitis
AMPA antagonists in, 15(NV), 62, 67
glutamate receptor blockade, 15(NV), 62, 67
thymic autoreactive T-cell repertoire role,

- 15(NV), 56
 Experimental colitis, interleukin 6 *trans* signaling, 583
 Expressed-sequence tags patents, revisions, 362(N)
- F**
 Facilitating cell surface marker, bone marrow transplantation, 866(NV), 904
 Familial Alzheimer disease, presenilin mutations, 1220(NV)
 Familial hemophagocytic lymphohistiocytosis, 27(NV)
 Fas-associated death domain protein, inflammatory gene expression activation, 790
 Fas engagement, liver regeneration acceleration, 920
 FasL, immune privilege mechanisms re-evaluation, 493(C)
 Fat transplantation, and diabetes studies, 263(NV)
 Fatty acid synthetase I, pyrazinamide inhibition, 977(NV), 1043
 Fatty liver disease reversal, metformin effect, mice, 998
 Favaloro, Rene, 1070(N)
 Fc receptors, anti-tumor cytotoxicity modulation, 373(NV), 443
 Fc α R1, serum IgA interactions, mucosal immunity, 680
 Feeding behavior, glucagon-like peptide-2 role, 802
 Fetal alcohol syndrome, mechanisms, 263(NV)
 Fetal hemoglobin, sickle cell disease, transgenic mice, 139(NV), 177
 Fetal immunization, DNA vaccine oral cavity delivery, 929
 Fetal loss, coagulation factors gene mutations, 1220(N)
 Fetal stem cells. *See* Human embryonic stem cells
 Fibroblasts, aging mechanism, DNA microarray analysis, 507(NV)
 Flow cytometry counting, CD34⁺ cells, 833(NT)
 FOG-2, heart development role, 864(NV)
 Folkman, Judah, 948(N)
 Follicular dendritic cells, scrapie pathogenesis, 719(L)
 Follicular epithelial cells, as skin epidermis source, 1095(NV)
 Food and Drug Administration, proposal to reform, 963(B)
 Food intake, glucagon-like peptide-2 role, 802
 Ford, Larry C., 614(N)
 Fra-1 overexpression, bone formation, 970(NV), 980
 Framingham Heart Study, commercialization, 721(N)
 Functional antibodies, design of, 123(C)
 Functional genomics, bioinformatics, 1071(N)
 Functional MRI, attention deficit/hyperactivity disorder, 470
 Fundacion Favaloro, 1070(N)
- G**
 Galanin-1 receptor up-regulation, excess colonic fluid production, 1048
 Gamma interferon, vascular xenogeneic rejection role, 497(NV), 549
 Gankyrin overexpression, retinoblastoma protein destabilization, hepatomas, 96
 Gastric atrophy attenuation, concurrent helminth and helicobacter infection, 536
 Gastric cancer, *Helicobacter pylori* link, 376(NV)
 Gastritis, concurrent helminth and helicobacter infection, 536
 Gender differences, HIV-1 genetic diversity, 23(NV), 71
 Gene expression
 in vivo magnetic resonance imaging, 256(NV), 351
 positron emission tomography, 933(NV)
 Gene patents, revisions, 362(N)
 Gene therapy
 annual meeting reinvigoration of field, 722(N)
 cancer Phase II clinical trial, 862(NV), 879
 cautious optimism, 717(E)
 clinical trial monitoring changes, 486(N)
 neural stem cells as vehicle, brain tumors, 369(C), 447
 Parkinson disease, 1207(NV)
 severe combined immunodeficiency, 623(NV)
 sickle cell disease, mouse model, 139(NV), 177
 Gene therapy death, 6(N)
 biotechnology industry response, 118(N)
 clinical trial monitoring changes, 486(N)
 safety wake-up call, 1(E)
 Senate subcommittee hearing, 235(N)
 Gene transfer, hematopoietic stem cells, 624(NV), 652
 Genetic databases, United Kingdom plan, 359(N)
 Genetic testing, insurance premium assessment use, UK, 1199(N)
 Genetically modified organisms, UK research difficulties, 364(N)
 Germ line protection, and cancer therapy, 1100(NV), 1109
 Glial cell line-derived neurotrophic factor, Parkinson disease gene therapy, 1207(NV)
 Glioma therapy
 cannabinoid agonists, 255(NV), 313
 chimeric poliovirus, 750(NV)
 neural stem cells, IL-4 delivery, 369(C), 447
 Global Alliance for Vaccines and Immunizations
 commercial boost, 363(N)
 fund raising, 238(N)
 Glucagon-like peptide-2, food intake regulation role, 802
 Glucocorticoid-responsive androgen receptor mutants, prostate cancer, 628(NV), 703, 939(Err)
 Glucose, transdermal monitoring using ultrasound, 347
 Glucose intolerance, glucose transporter 4 importance, 924
 Glucose transporter 4 targeted disruption, 924
 'Glue grant' announced, 1072(N)
 Glutamate receptors
 blockade of, multiple sclerosis model, 15(NV), 62, 67
 immunization against, neuroprotective effects, 383(NV)
 Government-University Research Partnership, 239(N)
 Graft-versus-host disease
 donor cell manipulation, 18(NV)
 and LIGHT pathway, 283
 Grafts. *See* Transplantation
 Gram-negative pathogens, autoimmune disease link, 215
 Green fluorescence protein
 neural progenitor cell expression, 271, 483(L)
 transgenic expression of, cardiomyopathy cause, 482(L)
 Greengard, Paul, 1196(N)
 Grinstein, Sergio, 485(N), 609(N)
 Group A streptococcal vaccine, Australian Aborigines, 455
 Guillain-Barré syndrome, endogenous sodium channel blocker role, 738(NV), 808
 Gulf War syndrome, magnetic resonance spectroscopy, 750(NV)
- H**
 HAART. *See* Highly active anti-retroviral therapy
 Hair follicle epithelial cells, skin epidermis source, 1095(NV)
 Hamilton, W.D., 367(Obit)
 Hantavirus, 11(B)
Hcrt mutation, early onset narcolepsy, 991
 Head and neck cancer, gene therapy clinical trial, 862(NV), 879
 Health Life Expectancy Rankings, 722(N)
 Heart disease
 bacterial infections role, 841(L)
 calcium signaling, 1221(C)
 Heart failure
 and calcineurin, 2(L)
 gene therapy, 512(NV)
 sarcolemmal reticulum function, 942(L)
 TAK1 role, transgenic mice, 556
 Heart function, calcium signaling, 1221(R)
 Heat-shock protein-70, chaperone and cytokine dual role, 429
Helicobacter pylori
 concurrent helminth infection, gastric atrophy attenuation, 526
 gastric cancer link, 376(NV)
 Helminth infection, gastric atrophy attenuation, 536
 Hemangioma risk, vascular endothelial growth factor gene therapy, 1102(NV)
 Hematopoietic stem cells
 engraftment facilitation, 18(NV)
 hepatic regeneration, 1212(NV), 1229
 long-term gene transfer, 624(NV), 652
 Notch signaling immortalization of, 1210(NV), 1278
 p27^{Kip1} effects, 1235
 Hepatectomy, Fas-induced apoptosis prevention, 920

- Hepatic regeneration, hematopoietic stem cells, 1212(NV), 1229
- Hepatitis B infection, hepatocyte xenotransplantation model, 327
- Hepatitis C virus, 1082(C)
- Hepatitis C virus infection
long-term immunological correlates of recovery, 578
outcome prediction, 512(NV)
vaccine advance, mouse model, 142(NV)
- Hepatitis delta virus infection, hepatocyte xenotransplantation model, 327
- Hepatocarcinogenesis, gankyrin overexpression, 96
- Hepatocyte transplantation
human hepatitis infections model, 327
variable therapeutic effect, mice, 320
- Hepatocytes
hematopoietic stem cell contribution, 1212(NV), 1229
NF- κ B immune response function, 573
PDX-1 induced conversion to β -cells, 505(NV), 568
TRAIL-induced apoptosis, 502(NV), 564
transplantation, 320, 327
- HER-2/neu*, PEA3 suppression of, tumorigenesis inhibition, 189
- Herpesvirus, atherosclerosis role, 979(NV)
- Heyward, William, 361(N)
- HF-1b* disruption, ventricular arrhythmias, 968(NV)
- Highly active anti-retroviral therapy
episomal HIV-1 replication persistence, 76
HIV-1 primary infection, viremia control, 1094(NV), 1140
and latent reservoir HIV-1 replication, 76, 82, 736(NV), 757
non-latent reservoir viral rebound, 736(NV), 757
- Hippocampus, neuronal progenitor cell isolation, 249(NV), 271, 483(L)
- HIV discovery, 372(B)
- HIV-1 evolution, 750(NV)
- HIV-1 genetics, gender differences, 23(NV), 71
- HIV-1 infection
CCR5 co-receptor mechanism, 769
mycophenolic acid control of, 735(NV), 762
naïve T-cell homeostasis impact, 976(NV), 1036
nuclear translocation mechanism, 626(NV)
oral polio vaccine theory, 1067(NV)
- HIV-1 nuclear translocation mechanism, 626(NV)
- HIV-1 pathogenesis, gender differences, 23(NV), 71
- HIV-1 protease mutations, online search engine for queries, 1290(NT)
- HIV-1 rebound, HAART discontinuation, 76, 82, 736(NV), 757
- HIV-1 replication
episome-specific PCR detection, HAART, 76
HAART limitations, 76, 82
latent reservoirs of, 76, 82
mycophenolic acid control of, 735(NV), 762
- HIV-1 reverse transcriptase mutations, online search engine for queries, 1290(NT)
- HIV-1/SIV chimeric virus, mucosal transmission protection, 129(NV), 200, 207
- HIV-1 specific CD4⁺ cells
homeostasis, 976(NV), 1036
latent virus source, 736(NV), 757
- HIV-1 therapy, 261(NV). *See also* Highly active anti-retroviral therapy
- HIV-1 transmission
and HIV-1 genetic diversity, 23(NV), 71
in vitro models, mucosa, 475(NT), 607(L)
mother-to-infant, mucosal IgG protection, 129(NV), 200
mucosal protection, IgGs, 129(NV), 200, 207
organ culture model, female genital tract, 475(NT), 607(L)
- HIV-1 vaccine
African trials planned, 844(N)
China's international meeting, 5(N)
design and construction of, Kenya trial, 951(C)
IgG mucosal protection, SHIV chimeric virus, 129(NV), 200, 207
Kenya clinical trial, 951(C)
NIH revamps clinical trials unit, 488(N)
QUEST collaborative trial, 1194(L)
South African trial, 1199(N), 1200(N)
UNAIDS guidelines, 363(N)
US NIAID funding, 844(N)
- HLA types, South African ethnic groups, 3(L)
- HRAS* oncogene, Kaposi sarcoma-associated herpesvirus oncogenesis mechanism, 1091(NV), 1121
- HTLV-1, South American origin, 232(L)
- Human cytomegalovirus, virion mRNA content, 863(NV)
- Human cytomegalovirus late protein VL94, autoimmunity link, 1183
- Human genome, 11(B)
- Human embryonic stem cells, 231(E)
activists threaten academic research funding, 119(N)
adult stem cells effect of, 747(NV)
American Heart Association support, 845(N)
Europe asks UK to reject cloning approval, 1068(N)
European bioethical discussion, 845(N)
Japanese guidelines, 239
NIH guidelines delay, 231(E)
Pope influences scientists, 1069(N)
UK approves research, 950(N)
UK policy speculation, 486(N)
University of Wisconsin sale of, 237(N)
US guidelines released, 1068(N)
US Senate subcommittee debate, 614(N)
- Huntingtin
expression block, 512(NV)
Hereditary Disease Foundation conference, 1063(E)
normal and mutant function, 1208(NV)
- Huntington disease
Hereditary Disease Foundation conference, 1063(E)
- huntingtin expression block, 512(NV)
minocycline mortality delay, mice, 797
normal and mutant huntingtin role
- Hyaluronic acid, *Plasmodium falciparum* adhesion, placenta, 25(NV), 86
- Hypocretins, narcolepsy role, 991
- Hypoxia-inducible factor-1 β , PR39 inhibition of, 49
- ## I
- Ibuprofen, Alzheimer's disease treatment, 973(NV)
- IgG, mucosal HIV transmission protection, 129(NV), 200, 207
- I κ B kinase, cyclopentenone prostaglandins inhibition of, 137(NV)
- Immune Tolerance Network, "Edmonton Protocol" commences, 950(N)
- Immunocompetent SCID-hu mice, 103(NT)
- Immunofluorescence, gamma interferon and IL-10 detection, 107(NT)
- Immunoglobulin framework-derived peptides, cytotoxic T-cell epitope function of, 667
- Immunoglobulin A, Fc α RI interactions, mucosal immunity, 680
- Immunologic 'ignorance,' vascularized organ transplants, 686
- Imperial College School of Medicine, 1070
- Infectious diarrhea, galanin-1 receptor up-regulation, 1048
- Infertility
ceramide analogs protective effects, mice, 1100(NV), 1109
spermatogonial cell transplantation, mice, 16(NV), 29
- Inflammatory disease, carbon monoxide therapeutic potential, 422
- Inflammatory response, signaling systems link, 137(NV)
- Influenza pandemic of 1918, 12(B)
- Influenza vaccine, needle-free powder delivery, 1187(NT)
- Informed consent, 615(C)
- Innate immune system, trophoblast pregnancy-specific component, 589, 838(Corr)
- Institutional Review Boards, 1193(E)
- Insulin-dependent diabetes. *See* Type I diabetes
- Insulin resistance
glucose transporter 4 importance, 924
metformin therapeutic mechanism, mice, 998
skeletal muscle respiratory uncoupling prevention strategy, 1092(NV), 1115
- Insurance premium assessment, genetic testing use, UK, 1199(N)
- Interferon- γ
coxsackievirus-induced myocarditis protection, 631(NV), 693
high-sensitivity immunofluorescence detection, 107(NT)
- Interleukin-2, p27^{kip1} inhibition of, 290
- Interleukin-4, neural stem cell delivery, gliomas, 369[©], 447
- Interleukin-6 *trans* signaling, intestinal inflammation

- pathogenic pathway, 583
- Interleukin-10, high-sensitivity immunofluorescence detection, 107(NT)
- Interleukin-12, transplantation regulation, 497(NV), 549
- International Financial Institution Advisory Commission HIV report, 491(N)
- Intestinal inflammation, interleukin-6 *trans* signaling role, 583
- Intestinal neoplasia, combinatorial chemoprevention, 974(NV), 1024
- Intrauterine growth retardation, thromboxane A₂ receptor role, 219
- Intravascular metastasis model, 100
- Iodide transporter expression, mammary tumors, 859(NV), 871
- Iron transporter, 263(NV)
- Ischemic peripheral neuropathy, VEGF gene transfer therapeutic angiogenesis, 379(NV), 405
- Islet cell transplantation, 750(NV)
- Iso citrate lyase, tuberculosis latent stage infection role, 979(NV)
- Israel, medical research quality decline, 9(N)
- Italy
- biomedical research budget, 9(N)
 - genomics project, 1071(N)
 - neuroscience network plans, 490(N)
- J**
- Japan
- human embryonic stem cell research guidelines, 239(N)
 - Institute of Medical Science career structure changes, 488(N)
- Juvenile Diabetes Foundation, research funding increase, 726(N)
- K**
- Kandel, Eric, 1196(N)
- Kaposi sarcoma-associated herpesvirus
- latent nuclear antigen oncogenesis mechanism, 1091(NV), 1121
 - reservoir in great apes, 1107(NV)
- Kay, Marguerite, 120(N)
- Kenya, HIV-1 vaccine clinical trial, 951(C)
- Kety, Seymour S., 727(Obit)
- Koren, Gideon, 364(N), 485(N), 609(N)
- Kourilsky, Philippe, 236(N)
- Kringle 5 lawsuit, 723(N)
- Krumlauf, Robert, 949(N)
- Ku80 function, 503(NV)
- L**
- Lamins, 136(NV)
- Langerhans cells, dengue virus target, 748(NV), 816
- Large multifunctional proteasome-2, in non-obese diabetic mouse, 1064(L)
- Lasker Awards, 1073(C), 1082(C), 10878(C)
- Leishmaniasis, miltefosine treatment, 27(NV)
- Leptin, diabetes role, 263(NV)
- Leukemia cell death, superoxide dismutase inhibition, 1105(NV)
- Life expectancy rankings, 722(N)
- LIGHT, immunoregulatory functions, mice, 283
- Limitin, lymphopoiesis inhibition, 659
- Lipid-tagged antibody fragments, as functional cell-surface receptors, 233(NT)
- Liver disease, hepatocyte transplantation variable therapeutic effect, 320
- Liver regeneration
- bone marrow cells role, 869(NV)
 - Fas engagement, 920
- Liver-stage antigen 3, malaria immunization, 1218(NV), 1258
- LMNA mutations, 136(NV)
- Locomotor sensitization, SPARC glycoprotein role, 910
- Lupus erythematosus. *See* Systemic lupus erythematosus
- Lustgarten Foundation, 605(E)
- M**
- Macrophage migration inhibitory factor, sepsis role, 140(NV), 164
- Magnetic resonance imaging
- attention deficit/hyperactivity disorder, 470
 - in vivo* transgene expression, 256(NV), 351
- Magnetic resonance microscopy, amyloid plaques, 20(NV)
- Magnetic resonance spectroscopy nosologic images, brain tumors, 1287(NT)
- Magnetofluorescent liposomes, 107(NT)
- Malaria, 941(E)
- challenges and initiatives, 941(E)
 - drug target identification, 898
 - European vaccine research, 234(L)
 - funding increase, Africa, 612(N)
 - immunity target identification, 689
 - immunization with liver-stage antigen 3, 1218(NV), 1258
 - MSP-1₁₉ vaccine antigen, functional conservation, 91
 - Nature Medicine* Special Focus website, 720(N)
 - P. falciparum* hyaluronic acid adhesion, placenta, 25(NV), 86
 - transmission-blocking vaccine development, 241(C)
 - vaccine obstacles, 955(C)
- Male infertility, spermatogonial cell transplantation, mice, 16(NV), 29
- Malignant glioma therapy, cannabinoid agonists, 255(NV), 313
- Mammary gland, iodide transporter expression, 859(NV), 871
- Marijuana, opposition to new research rules, 10(N)
- Maspin
- angiogenesis inhibition, 196
 - tumor suppression mechanism, 374(NV)
- Massachusetts Institute of Technology, neuroscience center, 362(N)
- Mast cell tryptase, neurogenic inflammation mechanism, PAR2 agonism, 134(NV), 151
- Mbeki, Thabo, 843(N)
- MCP Hahnemann University, censure escape, 724(N)
- Measles, DNA vaccine, 744(NV), 776, 1062(Err)
- Medical Research Council, research staff neglect accusation, 725(N)
- The Medical Scientist Training Program, 605(E)
- Medulloblastoma, REST/NRSF regulator, 826, 1062(Err)
- Mendoza, Carmen, 609(N)
- Meningococcal pathogenesis, functional genomics, 1215(NV), 1269
- Mental health research, funding distribution questioned, 237(N)
- Mesenchymal stem cells, xenogeneic transplantation, site-specific differentiation, 1282
- Messenger RNA 3' untranslated region, pathology 'hotspot?' 637(R)
- Metastatic tumors. *See* Tumor metastasis
- Metformin, fatty liver disease reversal, 998
- Mgat5-deficient mice, tumor suppression, 306
- MHC class Ib molecules, autoimmune disease link, 215
- MHC-peptide multimers, T cell detection and sorting, 707(NT)
- Michael Polanyi Center, 613(N)
- Mifepristone, "off label" research, 1196(N)
- Miltefosine, leishmaniasis treatment, 27(NV)
- Minocycline, Huntington disease mortality delay, mice, 797
- Mismatch repair, MLH3 identification, 19(NV)
- MIT neuroscience center, 362(N)
- Mitochondria, cell death control, 513(R)
- Mitogen-activated protein kinase pathway, carbon monoxide anti-inflammatory effects mechanism, 422
- Molecular mimicry
- coxsackievirus-induced myocarditis, 631(NV), 693
 - infection and autoimmune disease model, 215
- Molecular population genetics, malaria immunity target identification, 689
- Monoclonal antibodies, antitumor therapy, Fc receptors, 373(NV), 443
- Montagnier center fate, 235(N)
- Morphine sensitization, SPARC glycoprotein role, amygdala, 910
- MSP-1₁₉, functional conservation across *Plasmodium* species, 91
- Mucosal HIV transmission, *in vitro* models, 475(NT), 607(L)
- Mucosal immunity, serum IgA and FcαRI interactions, 680
- Mucosal SHIV neutralizing antibodies, 129(NV), 200, 207
- Multidrug resistance 1 gene, long-term transfer, 624(NV), 652
- Multiple sclerosis
- altered peptide ligand clinical trials, 1098(NV), 1167, 1176
 - AMPA antagonists in, 15(NV), 62, 67
 - endogenous sodium channel blocker role, 738(NV), 808

- glutamate receptor blockade, 15(NV), 62, 67
 multiple approaches, 15(NV), 56, 62, 67
 thymic autoreactive T-cell repertoire role, 15(NV), 56
- Murine lymphoma model, chemoresistance analysis, 1029
- Muscle differentiation, calcium regulation mechanism, 1216(NV)
- Muscle wasting, NF- κ B role, 1216(NV)
- Muscular dystrophy, gene therapy, golden retrievers, 635(NV)
- MYCN* amplification, caspase 8 suppression role, neuroblastomas, 498(NV), 529
- Mycobacterium tuberculosis*
 'cording' mechanism, 632 (NV)
 pyrazinamide mechanism, drug design implications, 977(NV), 1043
- Mycophenolic acid, HIV-1 replication control, 735(NV), 762
- Myelin basic protein₈₃₋₉₉, MS clinical trials, 1098(NV), 1167, 1176
- Myocardial hypertrophy, TAK1 role, transgenic mice, 556
- Myocarditis, coxsackievirus mechanism, 429, 631(NV), 693
- Myogenesis mechanism, 1216(NV)
- Myosin light chain kinase, sarcomere organization mediation, 183
- N**
- Narcolepsy
Hcrt mutation, early onset case, 991
 hypocretin peptides, 991
- National Cancer Institute, UK readiness question, 357(E), 360(N)
- National Institutes of Health
 Challenge Grants, program, 1197(N)
 clinical research progress report, 1201(C)
 gender biology research funding, 950(N)
 graduate student training programs expansion, 847(N)
 HIV vaccine unit restructurization, 488(N)
 pharmacogenetics initiative, 487(N)
 2001 budget plans announcement, 239(N)
- Natural killer cells, tumor cell recognition, 867(NV)
- Neisseria meningitidis* pathogenesis, functional genomics, 1215(NV), 1269
- Neovascularization
 thrombospondin-1 inhibition of, signals, 41
See also Angiogenesis
- Neural plasticity, and premature infant pain memories, 971(NV)
- Neural stem cells
 development potential, 747(NV)
 gene therapy vehicle, brain tumors, 369(C), 447
 safety, 369(C)
- Neural transplantation, 621(B), 634(NV)
- Neuroblastomas, caspase 8 suppression with *MYCN* amplification, 498(NV), 529
- Neurogenic inflammation, proteinase-activated receptor 2 agonists, 134(NV), 151
- Neuronal progenitor cells
 enhanced green fluorescent protein effect on, 483(L)
in vitro neurogenesis, 249(NV), 271, 483(L)
 retinal dystrophy grafting, rat model, 1211(NV)
- Neuronal repressor REST/NRSF, medulloblastoma regulator, 826
- Neuroprotective autoimmunity, glutamate receptors, 383(NV)
- Neuroscience research center, MIT gift, 362(N)
- NF- κ B
 hepatocyte immune function role, 573
 muscle wasting role, 1216(NV)
- NKG2D receptor, tumor cell killing activation, 867(NV)
- NMDA receptor, immunization against, neuroprotective effects, 383(NV)
- Nobel Prize in Physiology or Medicine, 1196(N)
- Non-obese diabetic mouse, proteasome activity, 1064(L)
- Non-steroidal anti-inflammatory drugs, Alzheimer disease treatment, 973(NV)
- Nosological images, magnetic resonance spectroscopy, brain tumors, 1287(NT)
- Notch signaling, hematopoietic stem cell immortalization, 1210(NV), 1278
- Novartis (Cambridge, UK), BioTransplant(Boston, US) merger, 1195(N)
- NREM sleep, neuronal control of, 510(NV)
- Nuclear envelope, lamins interaction, 136(NV)
- O**
- Obesity prevention, respiratory uncoupling prevention strategy, 1092(NV), 1115
- Office for Human Research Protection investigations, 946(N)
- Oka vaccine strain, frequent reactivation evidence, 381(NV), 451
- Olfactory ensheathing glia, spinal cord repair, 382(NV)
- Oligonucleotide arrays. *See* DNA microarray analysis
- Olivieri, Nancy, 364(N), 485(N), 609(N)
- ONYX-015
 chemotherapy combination, clinical trial, 862(NV), 879
 replication facilitation, 1128
- Oral cavity DNA vaccine delivery, fetal lambs, 929
- Oral polio vaccine-AIDS theory, contradictory evidence, 1067(N)
- Oral squamous cell carcinomas, genetics, 141(NV)
- Orexin, in enteric neurons, 130(NV)
- Organ culture model, HIV-1 transmission, 475(NT)
- Organ transplantation. *See* Transplantation
- Orphan drugs, NIH Challenge Grants program, 1197(N)
- 'Orphan receptors', cholesterol homeostasis role, 1104(NV)
- Osteoclasts, paramyxovirus upregulation of, 387(NV)
- Osteoporosis, statins potential use, 21(NV)
- Osteoprotegerin, bone cancer pain treatment, 504(NV), 521, 838(Err)
- Osteosclerosis, AP-1 transcription factors role, 970(NV), 980, 985
- Otog* function, 142(NV)
- P**
- P14^{ARF} loss, adenovirus mutant *d/1520* replication, 1128
- p21, sex-linked lupus development role, 171
- p27^{Kip1}, anergy role, 290
- p53
 and adenovirus mutant *d/1520* use, 1128
 maspin gene regulation, 374(NV)
- p56^{lck}, coxsackievirus B3-mediated heart disease role, 429
- Paget disease, paramyxoviruses role, 387(NV)
- Pain memories, premature infants, 971(NV)
- Pancreatic stem cells, insulin-dependent diabetes reversal, 250(NV), 278
- Paradoxical sleep, 245(B)
- Parainfluenza virus type-1, RhoA as antiviral target, 35
- Parathyroid hormone, thymus as secondary source of, 860(NV)
- Parkinson disease
 glial cell line-derived neurotrophic factor delivery, 1207(NV)
 new models, 387(NV)
- Pasteur Institute reform, 236(N)
- Patient safety, HHS criticizes US research centers, 611(N)
- PDX-1 induced insulin gene expression, hepatocytes, 505(NV), 568
- PEA3, *HER-1/neu* suppression, tumorigenesis inhibition, 189
- Pediatric Rule, new drug applications, 1069(N)
- Pemphigus foliaceus pathogenesis, 869(NV), 1213(NV), 1275
- Perforin, familial hemaphagocytic lymphohistiocytosis role, 27(NV)
- Peripheral vasoconstriction, plethysmographic detection, REM sleep, 606(L)
- Pharmacogenetics
 NIH initiative, 487(N)
 private-public partnerships need, 48(E), 487(N)
- Photoreceptor disc defects, and retinal disease, 508(NV)
- Photosensitive epilepsy, 263(NV)
- Physician scientists
 concern over numbers of, 605(E)
 UK plans, 490(N)
- Physics, and biomedical research, 113(E)
- Phytomedicines, FY00 congressional priority, 7(N)
- Pigmentation restoration, gene therapy approach, 27(NV)
- Pingelapese color blindness, 746(NV)
- Placebo clinical trial ethics, developing countries, 1198(N)
- Placental malaria, *P. falciparum* hyaluronin acid adhesion, 25(NV), 86
- Plasmodium berghei*, δ -aminolevulinatase

- as drug target, 898
- Plasmodium falciparum*
hyaluronic acid adhesion, placenta, 25(NV), 86
immunity target identification, 689
liver-stage antigen 3 protection against, 1218(NV), 1258
ring-stage infected erythrocytes, cytoadhesion, 1264
- Plasmodium* species, MSP-1₁₉, functional conservation, 91
- Plethysmography, peripheral vasoconstriction detection, REM sleep, 606(L)
- Pluripotent stem cells
insulin-dependent diabetes reversal, 250(NV), 278
See also Human embryonic stem cells
- Poly-Q tracts, neurodegeneration role, 27(NV)
- Population genetics, malaria immunity target identification, 689
- Positron emission tomography
reporter gene expression imaging, 933(NT)
tumor-specific antibody fragmentation, 869(NV)
- Post-transfusion hepatitis, 1082(C)
- PowerJect vaccine delivery, 1187(NT)
- PR39, angiogenesis regulation, 49, 356(Err)
- Pre-eclampsia, neurokinin β link, 750(NV)
- Pregnancy, trophoblast innate immune response role, 589, 838(Corr)
- Pregnancy complications, coagulation factors gene mutations, 1220(NV)
- Premature infants, pain memories, 971(NV)
- Presenilin mutations, capacitative calcium entry downregulation, 1220(NV)
- Prion protein. *See also* Transmissible spongiform encephalopathy
amyloidosis link, 751(R)
human enteric nervous system expression, 840(L)
normal function, 1107(NV)
- Private-public partnerships, 481(E), 617(C)
- Proline racemase, *T. cruzi* B-cell mitogen, 865(NV), 890
- Prostate cancer
androgen escape mechanism, 628(NV), 703, 939(Err)
doxorubicin-peptide 'prodrug' selectivity, 1248
troglitazone therapeutic potential, 1107(NV)
- Prostate-specific antigen, peptide-doxorubicin 'prodrug' activation, tumor cell killing, 1248
- Proteasome activity, non-obese diabetic mouse, 27(NV), 1064(L)
- Proteinase-activated receptor 2 agonists, neurogenic inflammation, 134(NV), 151
- Public health
HIV health care needs link, 261(NV)
public-private partnerships for, 617(C)
- Public-private partnerships, 481(E), 617(C)
- PubMed Central, 496(N)
- Pulmonary hypertension reversal, serine elastase inhibitor, 698
- Pyrazinamide, fatty acid synthetase I inhibition, 977(NV), 1043
- Q**
The Quest trial, 1194(L)
- R**
Radioiodide, in breast cancer, 859(NV), 871
RAGE regulation
amyloidosis mechanism, 633(NV), 643
cancer suppression, 635(NV)
Reactive oxygen species, cancer therapy target, 1105(NV)
Recombinant adeno-associated virus vector, *cis*-activation strategy, 595(NT)
REM sleep, peripheral vasoconstriction, plethysmographic detection, 606(L)
Renal cell carcinoma
blood stem cell treatment, 1107(NV)
tumor cell-dendritic cell hybrid vaccine, 252(NV), 332
Renault, Beatrice, 4(N)
Reporter gene expression, PET imaging, 933(NT)
Research!America, 613(N)
Research data access, White House OMB rules, 8(N)
Research ethics, 615(C)
Respiratory syncytial virus, RhoA as antiviral target, 35
REST/NRSF, medulloblastoma regulator, 826, 1062(Err)
Retinal disease, photoreceptor disc defect link, 508(NV)
Retinal dystrophy, neural grafts, rat model, 1211(NV)
Retinitis pigmentosa, diltiazem rod photoreceptor rescue, 116(L)
Retinoblastoma-E2F pathway, KSHV oncogenesis mechanism, 1091(NV), 1121
Retinoblastoma protein, destabilization by gankyrin overexpression, 96
Retinoid X receptor heterodimers, cholesterol regulation, 1104
Rheumatoid arthritis, CD40 agonist antibody treatment, 629(NV), 673
RhoA-derived peptide, syncytium formation inhibition, 35
Rhodopsin, and light-induced retinal degeneration, 508(NV)
Rituximab, 373(NV), 443
'River theory,' 489(N)
Rod photoreceptor rescue, diltiazem use, 116(L)
Royal Society 'River theory' discussion, 489(N)
- S**
S-phase cells, visualization, 387(NV)
Sachs, Jeffrey, 491(N)
Salem witch trials, 127(B)
Salk-UCSD institute? 489(N)
Santos, Eugenio, 238(N)
Sarcomere organization, myosin light chain kinase mediation, hypertrophy, 183
Sarcoplasmic reticulum function, heart failure, 942(L)
Schizophrenia, genetics, 253(NV)
SCID-hu immunocompetent mice, antigen-specific immune response, 103(NT)
Scientific misconduct, 946(N)
Scrapie, follicular dendritic cells role, 719(L)
Secretory leukocyte protease inhibitor, wound healing role, 1147
Selective estrogen receptor modulators, 960(C)
Sepsis
macrophage migration inhibitory factor role, 140(NV), 164
superoxide anions role, 979(NV)
Serine elastase inhibitors, pulmonary hypertension reversal 698
Severe combined immunodeficiency disease
CD45 mutations, 343
gene therapy, 623(NV)
Sex differences. *See* Gender differences
Shelby law, 121(N)
Shiga toxicogenic infections, 'probiotic' treatment, 257(NV), 265
Sickle cell disease, gene therapy, mouse model, 139(NV), 177
Signature-tagged mutagenesis, *N. meningitidis*, 1215(NV), 1269
Simian-human immunodeficiency virus
IgG mucosal protection, 129(NV), 200, 207
vaccine advance, 1220(NV)
Simian immunodeficiency virus, primary infection viremia control, 1094(NV), 1140
Simvastatin, angiogenesis promotion, molecular pathway, 965(NV), 1004
Single-chain antibody fragments, lipid-tagging method, 223(NT)
Skin grafts, combined costimulatory blockade failure, 115(L)
Skin stem cells, hair follicular epithelial cells as source of, 1095(NV)
Sleep-promoting neurons, identification of, 510(NV)
Sodium channel blocker, demyelinating disease role, 738(NV), 808
South Africa
HIV/AIDS policy inactivity, 843(N)
HIV mixed messages, 1200(N)
HIV vaccine trial, 1199(N), 1200(N)
HLA types, 3(L)
Soybeans, infant leukemias role, 512(NV)
Space travel-induced bone loss, 635(NV)
Spain
oncology center under threat, 847(N)
oncology research centers, 238(N)
Oncology Research Institute's scientists win reprieve, 485(N)
'Spanish' influenza pandemic of 1918, 12(B)
SPARC glycoprotein, morphine sensitization mechanism, 910
Spermatogonial transplantation, fertility restoration, mice, 16(NV), 29
Sphingosine-1-phosphate therapy, oocyte apoptosis

INDEX

- suppression, 1100(NV), 1109
- Spinal cord injury
functional recovery definition, 358(L)
human olfactory ensheathing glial cell transplants, 382(NV)
- Split AAV vectors strategy, 599(NT)
- Squamous cell carcinoma, gene therapy clinical trial, 862(NV), 879
- Staphylococcal scalded-skin syndrome, 1213(NV), 1275
- Statins
anabolic effects on bone, 21(NV)
angiogenesis promotion, Akt activation, 965(NV), 1004
- Stem cells
developmental potential, 747(NV)
p27^{Kip1} effects, 1235
somatic support cells regulation of, 1220(NV)
See also Human embryonic stem cells
- Stop TB program, 491(N)
- Stowers Institute, 949(N)
- Straus, Stephen, 240(N)
- Streptococcus pyogenes
crystal structure features, 387(NV)
toxic shock syndrome protection, 414
- Stress, and depression, 733(B)
- Stroke, neuroprotective autoimmunity, glutamate receptors, 383(NV)
- Stromal cell derived factor-1, T-cell repulsive response to, 543
- Sudden cardiac death, *HF-1b* null mice, 968(NV)
- Superantigen, therapeutic peptide antagonist, 378(NV), 414
- 'Supercourse' proposal, 358(L)
- Superoxide dismutase inhibition, cancer therapy, 1105(NV)
- Systemic lupus erythematosus
p21 role, model, 171
and thymocyte positive selection disruption, 259(NV), 298
- Systemic sclerosis, human cytomegalovirus late protein UL94 link, 1183
- T**
- T cell receptor excision circle, HIV infection, 976(NV), 1036
- T cells
activation domain, 378(NV), 414
active repulsive response to chemokine, 543
antigen-specific suppression, 782
B-cell malignancies induction of immunogenic peptides, 667
CD4 activation, video microscopy, 1097(NV)
chronic myelogenous leukemia elimination, 1018
cytokines effect, graft rejection, 497(NV), 549
detection and sorting, 707(NT)
homeostasis of, HIV impact, 976(NV), 1036
p21 role in proliferation of, 171
p27^{Kip1} anergy role, 290
paradoxical inhibition, CTLA-4 blockade, 211
tumor cell target recognition, 867(NV)
- virus- and tumor-specificity detection, 1056(NT)
- TAK1, heart failure role, transgenic mice, 556
- Tamoxifen, estrogen receptor biology, 960(C)
- Telomerase-deficient mouse, 849(C), 852(C)
- Telomerase reverse transcriptase RNA transfected dendritic cells, tumor immunity, 966(NV), 1011
- Telomere biology, human versus mouse, cancer, 849(C), 852(C)
- TERT RNA transfected dendritic cells, tumor immunization, 966(NV), 1011
- 3' untranslated mRNA region, pathology 'hotspot,' 637(R)
- Thromboembolic complications, CD40 ligand blockade, 114(L)
- Thrombospondin-1, neovascularization inhibition, signals, 41
- Thromboxane A₂ receptor, intrauterine growth retardation role, 219
- Thymic dysfunction impact, HIV infection, 976(NV), 1036
- Thymic T-cell repertoire, and multiple sclerosis, 15(NV), 56
- Thymocytes, autoimmune disease mechanism, 259(NV), 298
- Thymus, parathyroid hormone source, 860(NV)
- Toxic shock syndrome protection, superantigen antagonist, 378(NV), 414
- TRAIL, apoptosis induction, normal human hepatocytes, 502(NV), 564
- Transcription factors, cellular transformation regulation, 742(NV)
- Transfusion-associated hepatitis, 1082(C)
- Transgene expression, *in vivo* magnetic resonance imaging, 256(NV), 351
- Transmissible spongiform encephalopathies
follicular dendritic cells role
yeast prions, 751(R)
- Transplantation
allocation squabble, US, 611(N)
combined costimulatory blockade failure, 115(L)
cytokine regulation, 497(NV), 549
hepatocyte variable therapeutic effect, 320
HIV patients, 365(N)
nerve cells, 621(B), 634(NV)
neuronal progenitor cells, hippocampus, 249(NV), 271
pancreatic stem cells, 250(NV), 278
and secondary lymphoid tissue absence, immunologic 'ignorance,' 686
- Trastuzumab, 373(NV), 443
- Troglitazone, prostate cancer protection, 1107(NV)
- Trophoblast, pregnancy-specific innate immune system component, 589, 838(Corr)
- Trypanosoma cruzi*, Chagas disease mechanism, 865(NV), 890
- Trypanosome survival, cell death relationship, 142(NV)
- Trypsin, neurogenic inflammation role, PAR2 agonism, 134(NV), 151
- Tuberculosis
'cording' mechanism, *pcaA*, 632(NV)
isocitrate lyase role, 979(NV)
pyrazinamide mechanism, drug design implications, 977(NV), 1043
Stop TB initiative, 491(NV)
- Tumor cells, natural killer cell attack mechanism, 867(NV)
- Tumor growth suppression, Mgat5 role, 306
- Tumor metastasis
chemotherapy dosage design, 500(NV)
Fc receptors cytotoxicity modulation, 373, 443
intravascular endothelial origin, model, 100
maspin gene mechanism, 374(NV)
mechanisms, 500(NV)
Mgat5 inhibitors role, 306
- Tumor necrosis factor-related apoptosis-inducing ligand. *See* TRAIL
- Tumorigenesis, *HER-2/neu* overexpression suppression, 189
- Type I diabetes
pancreatic stem cell reversal of, 250(NV), 278
PDX-1-induced insulin gene expression, hepatocytes, 505(NV), 568
proteasome defect, 27(NV), 1064(L)
- Type II diabetes
CAPN10 gene association, 1107(NV)
glucose transporter 4 importance, 924
skeletal muscle respiratory uncoupling prevention strategy, 1092(NV), 1115
- Typhoon Lengkieki, 746(NV)
- Tyrosine phosphatase CD45 gene mutations, and SCID, 343
- Tyrosinemia type I, hematopoietic stem cell therapy, 1212(NV), 1229
- U**
- Ubiquitin system, 1073(C)
- Ulcerative colitis, interferon 6 *trans* signaling role, 583
- Ultrasound, glucose transdermal monitoring, 347
- UN peacekeeping troops, AIDS threat, 949(N)
- UNAIDS, HIV vaccine guidelines, 363(N)
- Uncoupling protein expression, obesity prevention, 1092(NV), 1115
- United Nations, HIV/AIDS threat to world peace acknowledged, 117(N)
- University of California San Francisco, gender discrimination charge, 359(N)
- University of Nebraska Medical Center, fetal stem cell research threatened, 119(N)
- V**
- Vaccination
global initiative, 238(N)
Welfare-based sanctions program expanded, 119(N)
- Vaccines
commercial boost, 363(N)
dendritic cells-renal carcinoma cells, tumor regression, 252(NV), 332

- functional antibody design, 123(C)
- global initiative, 238(N)
- needle-free powder delivery, 11878(NT)
- Third World development, industry perspective, 723(N)
- Varicella-zoster Oka vaccine, 381(NV),451
- Vascular endothelial growth factor
 - angiogenesis mechanism, 131(NV)
 - angio-genesis or angiogenesis stimulation? 1102(NV)
 - ischemic peripheral neuropathy therapeutic angiogenesis, 379(NV), 405
- Vascular grafts, cytokine regulation, 497(NV), 549
- Vascular leakage protection, angiotensin-1, 460
- Vascular smooth muscle cells, Fas/FADD-mediated inflammation, 790
- Ventricular cardiomyocytes, *HF-1b* null mice, 968(NV)
- Ventrolateral preoptic hypothalamic region, sleep control, 510(NV)
- Veronesi, Umberto, 610(N)
- Vesicular stomatitis virus, oncolytic effects, 821
- West Nile virus, US resurgence anticipated, 947(N)
- Women
 - clinical trials enrollment progress, 612(N)
 - HIV-1 genetic diversity, 23(NV),71
 - NIH gender biology research funding, 950(N)
- Women in science, 1089(B)
- World AIDS Conference, 613(N),839(E)
- World Health Organization
 - HIV drug policy attacked, 726(N)
 - institutional framework problems, 481(E), 491(N)
- Stop TB participation, 491(N)
- Wound healing, secretory leukocyte protease inhibitor role, 1147
- Wounds, tumor similarity, angiogenesis, 979(NV)
- Xenogeneic endothelial cells, antitumor immunotherapy, 1160
- Xenotransplantation, 963(B)
 - cytokine regulation of, 497(NV),549
 - hepatocytes, hepatitis infection model, 327
 - Novartis-BioTransplant merger signals research shift, 1195(N)
 - UKXIRA delays potential trial approvals, 10(N)
- Yeast prions, 751(R)